Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.

Safroneeva, Ekaterina; Vavricka, S; Fournier, N; Seibold, Frank Werner; Mottet, C; Nydegger, A; Ezri, J; Straumann, A; Rogler, G; Schoepfer, A M; Juillerat, Pascal; Swiss IBD Cohort, Study Group (2015). Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Alimentary pharmacology & therapeutics, 42(5), pp. 540-548. Wiley-Blackwell 10.1111/apt.13307

[img] Text
Safroneeva AlimentPharmacolTher 2015_p540.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (484kB) | Request a copy
[img] Text
Safroneeva AlimentPharmacolTher 2015_p540_corrigendum.pdf - Other
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (135kB) | Request a copy

BACKGROUND Studies that systematically assess change in ulcerative colitis (UC) extent over time in adult patients are scarce. AIM To assess changes in disease extent over time and to evaluate clinical parameters associated with this change. METHODS Data from the Swiss IBD cohort study were analysed. We used logistic regression modelling to identify factors associated with a change in disease extent. RESULTS A total of 918 UC patients (45.3% females) were included. At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4-16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent. The following factors were identified to be associated with disease progression: treatment with systemic glucocorticoids [odds ratio (OR) 1.704, P = 0.025] and calcineurin inhibitors (OR: 2.716, P = 0.005). No specific factors were found to be associated with disease regression. CONCLUSIONS Over a median disease duration of 9 [4-16] years, about two-thirds of UC patients maintained the initial disease extent; the remaining one-third had experienced either progression or regression of the disease extent.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine

UniBE Contributor:

Safroneeva, Ekaterina; Seibold, Frank Werner and Juillerat, Pascal

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0269-2813

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

09 Feb 2016 16:21

Last Modified:

15 Sep 2017 15:36

Publisher DOI:

10.1111/apt.13307

PubMed ID:

26148503

BORIS DOI:

10.7892/boris.76894

URI:

https://boris.unibe.ch/id/eprint/76894

Actions (login required)

Edit item Edit item
Provide Feedback